These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 34168005)

  • 1. Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem.
    Poels K; Neppelenbroek SIM; Kersten MJ; Antoni ML; Lutgens E; Seijkens TTP
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34168005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease.
    Lutgens E; Seijkens TTP
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32034065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Increased Understanding of the Association Between Atherosclerosis and Immune Checkpoint Inhibitors.
    Ellison JM; Nohria A
    Curr Cardiol Rep; 2023 Aug; 25(8):879-887. PubMed ID: 37395892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque.
    Drobni ZD; Alvi RM; Taron J; Zafar A; Murphy SP; Rambarat PK; Mosarla RC; Lee C; Zlotoff DA; Raghu VK; Hartmann SE; Gilman HK; Gong J; Zubiri L; Sullivan RJ; Reynolds KL; Mayrhofer T; Zhang L; Hoffmann U; Neilan TG
    Circulation; 2020 Dec; 142(24):2299-2311. PubMed ID: 33003973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atherosclerotic cardiovascular events associated with immune checkpoint inhibitors in cancer patients.
    Tajiri K; Sekine I
    Jpn J Clin Oncol; 2022 Jul; 52(7):659-664. PubMed ID: 35348725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors in cancer: the increased risk of atherosclerotic cardiovascular disease events and progression of coronary artery calcium.
    Gong B; Guo Y; Li Y; Wang J; Zhou G; Chen YH; Nie T; Yang M; Luo K; Zheng C; Pan F; Liang B; Yang L
    BMC Med; 2024 Jan; 22(1):44. PubMed ID: 38291431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
    Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of immune checkpoint inhibitor mediated cardiovascular toxicity: A systematic review and meta-analysis.
    Malaty MM; Amarasekera AT; Li C; Scherrer-Crosbie M; Tan TC
    Eur J Clin Invest; 2022 Dec; 52(12):e13831. PubMed ID: 35788986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atherosclerosis With Immune Checkpoint Inhibitor Therapy: Evidence, Diagnosis, and Management:
    Suero-Abreu GA; Zanni MV; Neilan TG
    JACC CardioOncol; 2022 Dec; 4(5):598-615. PubMed ID: 36636438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
    Bhatlapenumarthi V; Patwari A; Harb AJ
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular events after cancer immunotherapy as oncologic emergencies: Analyses of 610 head and neck cancer patients treated with immune checkpoint inhibitors.
    Reyes-Gibby CC; Qdaisat A; Ferrarotto R; Fadol A; Bischof JJ; Coyne CJ; Lipe DN; Hanna EY; Shete S; Abe JI; Yeung SJ
    Head Neck; 2024 Mar; 46(3):627-635. PubMed ID: 38151809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape.
    Zhu H; Ivanovic M; Nguyen A; Nguyen PK; Wu SM
    J Mol Cell Cardiol; 2021 Nov; 160():121-127. PubMed ID: 34303670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of glucocorticoids in the management of immunotherapy-related adverse effects.
    Wang H; Zhou J; Guo X; Li Y; Duan L; Si X; Zhang L
    Thorac Cancer; 2020 Oct; 11(10):3047-3052. PubMed ID: 32893490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxicity of Immune Checkpoint Inhibitors.
    Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
    Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy.
    Dimitriou F; Hogan S; Menzies AM; Dummer R; Long GV
    Eur J Cancer; 2021 Nov; 157():214-224. PubMed ID: 34536945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitor Therapy Aggravates T Cell-Driven Plaque Inflammation in Atherosclerosis.
    Poels K; van Leent MMT; Boutros C; Tissot H; Roy S; Meerwaldt AE; Toner YCA; Reiche ME; Kusters PJH; Malinova T; Huveneers S; Kaufman AE; Mani V; Fayad ZA; de Winther MPJ; Marabelle A; Mulder WJM; Robert C; Seijkens TTP; Lutgens E
    JACC CardioOncol; 2020 Nov; 2(4):599-610. PubMed ID: 34396271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity.
    Khunger A; Battel L; Wadhawan A; More A; Kapoor A; Agrawal N
    Curr Oncol Rep; 2020 Jun; 22(7):65. PubMed ID: 32514647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System.
    Wang H; Yang H; Zhou X; Zhang X
    Clin Ther; 2023 Feb; 45(2):151-159. PubMed ID: 36682994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
    Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
    J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibition alters the inflammatory cell composition of human coronary artery atherosclerosis.
    Newman JL; Stone JR
    Cardiovasc Pathol; 2019; 43():107148. PubMed ID: 31518915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.